Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
AC0010 Maleate Capsules is a new, irreversible, Epidermal Growth Factor Receptor (EGFR)
mutation selective Tyrosine Kinase Inhibitor.Aim at local advanced or metastatic non-small
cell lung cancer patients with EGFR mutation or T790M drug-resistant mutation. The molecular
mechanism: by irreversible combining the EGFR-RTKs ATP binding site of cell, selectively
suppress the activities of EGFR tyrosine kinase phosphorylation, block the sigal signal
transduction system of EGFR, and close the function of ras/raf/MAPK downstream. at last block
the tumor cell growth by EGFR induction, and promotes apoptosis. AC0010 Maleate Capsules has
three characters: 1. Irreversible combination with EGFR; 2.Efficient suppress the EGFR mutant
tumor cell and has no suppression to EGFR wild-type cell; 3. Efficient suppress the EGFR
T790M drug-resistant mutation tumor cell.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Acea Bio (Hangzhou) Co., Ltd. Hangzhou ACEA Pharmaceutical Research Co., Ltd. Hangzhou ACEA Pharmaceutical Research Co.,Ltd.